XORTX Therapeutics Inc (TSE:XRTX)
:XRTX
Want to see TSE:XRTX full AI Analyst Report?
XRTX Stock Chart & Stats
C$0.78
C$0.05(2.94%)
At close: 4:00 PM EST
C$0.78
C$0.05(2.94%)
Day’s Range― - ―
52-Week RangeC$2.43 - C$9.85
Previous CloseN/A
Volume514.00
Average Volume (3M)11.08K
Market Cap
C$4.40M
Enterprise ValueC$402.49K
Total Cash (Recent Filing)C$250.45K
Total Debt (Recent Filing)C$15.07K
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,392,444
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)C$3.25M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low reported debt materially reduces bankruptcy and refinancing risk for a development-stage biotech. With minimal interest burden, management has flexibility to fund R&D from equity raises or partnerships, preserving operating runway choices over the next several quarters.
Improving Loss TrajectoryA substantial reduction in operating losses versus 2022 signals improving cost control or streamlined development spend. Sustained narrowing of losses increases the probability the company can reach value-driving clinical inflection points with lower incremental funding requirements.
Focused Clinical-stage PipelineA concentrated product strategy targeting hyperuricemia and kidney disease provides clear go-to-market focus and potential for regulatory clarity. Specialization can improve trial design efficiency and make the company an attractive partner or acquisition target in a structurally growing renal therapeutics market.
Bears Say
No RevenueAbsence of commercial revenues means the company is wholly dependent on external financing or partnership milestones to sustain operations. This structural funding dependence elevates dilution risk and creates ongoing uncertainty about long-term self-sufficiency absent successful trials or deals.
Persistent Cash BurnConsistent negative operating and free cash flow indicates the company is not yet on a path to self-funding. Continued burn pressures management to secure capital on schedule, which can force timing-sensitive dilution or suboptimal partner terms that reduce long-term shareholder value.
Shrinking Equity BaseA materially reduced equity base signals accumulated losses and potential prior dilution, weakening the company’s balance sheet resilience. With a smaller capital cushion, future shocks or higher-than-expected trial costs could more rapidly impair liquidity and heighten financing urgency.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$2.42 and its highest was C$9.85 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$4.40M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 70 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -C$0.806 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.806.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,392,444 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.806 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20.288%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---